204 related articles for article (PubMed ID: 28801316)
1. Barriers to the use of buccal and intranasal fentanyl for breakthrough pain in paediatric palliative care: an exploratory survey.
Harrop E; Jamieson L; Choy TH; Ho WHP; Wong ICK
BMJ Support Palliat Care; 2018 Sep; 8(3):355-356. PubMed ID: 28801316
[No Abstract] [Full Text] [Related]
2. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
[TBL] [Abstract][Full Text] [Related]
3. The management of wound-related procedural pain (volitional incident pain) in advanced illness.
Gallagher R
Curr Opin Support Palliat Care; 2013 Mar; 7(1):80-5. PubMed ID: 23150425
[TBL] [Abstract][Full Text] [Related]
4. Fentanyl for breakthrough pain: a systematic review.
Davis MP
Expert Rev Neurother; 2011 Aug; 11(8):1197-216. PubMed ID: 21797660
[TBL] [Abstract][Full Text] [Related]
5. How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion.
England R; Maddocks M; Manderson C; Zadora-Chrzastowska S; Wilcock A
BMJ Support Palliat Care; 2011 Dec; 1(3):349-51. PubMed ID: 24653483
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review.
Rogríguez D; Urrutia G; Escobar Y; Moya J; Murillo M
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):228-46. PubMed ID: 26458018
[TBL] [Abstract][Full Text] [Related]
7. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation.
Takigawa C; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
Jpn J Clin Oncol; 2015 Jan; 45(1):67-74. PubMed ID: 25381384
[TBL] [Abstract][Full Text] [Related]
8. Patient satisfaction with intranasal fentanyl for breakthrough pain.
Veldhorst-Janssen NM; Fiddelers AA; Zandstra H; Kessels AG; Zandstra H; Marcus MA; Neef C; van der Kuy PH
J Palliat Med; 2012 Jun; 15(6):631-2. PubMed ID: 22656053
[No Abstract] [Full Text] [Related]
9. Fentanyl pectin nasal spray for breakthrough cancer pain.
Torres LM; Trinidad JM; Calderón E; Benitez D; Perelman M
Int J Palliat Nurs; 2015 Mar; 21(3):114-6. PubMed ID: 25815759
[No Abstract] [Full Text] [Related]
10. [Not all pains are the same: breakthrough pain in cancer patients. A case report].
Gunnellini M
Recenti Prog Med; 2018 Nov; 109(11):6e-10e. PubMed ID: 30565580
[TBL] [Abstract][Full Text] [Related]
11. Buccal opioids for breakthrough pain in children with life-limiting conditions receiving end-of-life care.
Norman C; Maynard L
Int J Palliat Nurs; 2019 Oct; 25(10):472-479. PubMed ID: 31755841
[TBL] [Abstract][Full Text] [Related]
12. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
Mercadante S; Prestia G; Adile C; Casuccio A
J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
[TBL] [Abstract][Full Text] [Related]
14. Use of nasal fentanyl for cancer pain: A pharmacoepidemiological study.
Fredheim OM; Mahic M; Skurtveit S; Borchgrevink PC
Palliat Med; 2015 Jul; 29(7):661-6. PubMed ID: 25762579
[TBL] [Abstract][Full Text] [Related]
15. Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
Mercadante S
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):9-13. PubMed ID: 25359295
[TBL] [Abstract][Full Text] [Related]
16. [Management of breakthrough cancer pain].
Sláma O
Klin Onkol; 2013; 26(3):191-4. PubMed ID: 23763322
[TBL] [Abstract][Full Text] [Related]
17. Use of oral formulations of fentanyl for breakthrough cancer pain.
Handsaker S; Dempsey L; Fabby C
Int J Palliat Nurs; 2015 Apr; 21(4):168, 170-2. PubMed ID: 25901588
[No Abstract] [Full Text] [Related]
18. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
19. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R
Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816
[TBL] [Abstract][Full Text] [Related]
20. Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain.
Passik SD; Narayana A; Yang R
Pain Med; 2014 Aug; 15(8):1365-72. PubMed ID: 24666664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
